TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 28.2nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 548nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 518nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 83.3nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 15nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 82.5nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 28.2nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 1.32E+3nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 785nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: >2.00E+4nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 296nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 286nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 13.5nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 1.05E+3nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 90.1nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 13nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 466nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 199nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 3.83E+3nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 144nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 44.1nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 2.98E+3nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 138nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 2.66E+3nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 54.1nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 86.7nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 254nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 4.61E+3nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 50nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 147nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 121nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 1.76E+4nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 71nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 358nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 4.79E+3nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 159nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 59.5nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 12.5nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: >2.00E+4nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 30nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 9.98nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 768nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 6.65nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 247nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 1.74E+4nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 119nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 1.07E+3nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 53nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 763nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair
TargetN-lysine methyltransferase SMYD2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 64.8nMpH: 9.0Assay Description:SMYD2 inhibitory activities of the compounds described in the present invention were quantified using a scintillation proximity assay (SPA) which mea...More data for this Ligand-Target Pair